Coronavirus: US firm Eli Lilly pauses clinical trial of antibody drug over safety concerns,

An independent safety board will review the data on October 26 and advise the National Institutes of Health if the trial can resume., An independent safety board will review the data on October 26 and advise the National Institutes of Health if the trial can resume., Read More